Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lung Cancer (Locally Advanced or Metastatic)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05880706
What this trial is testing

BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 198
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398
Early research (Phase 1)Not Yet RecruitingNCT07583316
What this trial is testing

First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors

Who this might be right for
Lung Cancer (Locally Advanced or Metastatic)Esophagus CancerHead and Neck Cancer+1 more
Corregene Biotechnology Co., Ltd 192
Testing effectiveness (Phase 2)Looking for participantsNCT03093116
What this trial is testing

Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid Tumors
Turning Point Therapeutics, Inc. 500
Testing effectiveness (Phase 2)UnknownNCT05007938
What this trial is testing

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 30
Early research (Phase 1)Active Not RecruitingNCT05653882
What this trial is testing

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Who this might be right for
Solid TumorNon Small Cell Lung CancerMelanoma+2 more
Asher Biotherapeutics, Inc. 552
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Not applicableStudy completedNCT02760225
What this trial is testing

Pembrolizumab-PET Imaging

Who this might be right for
MelanomaNon-small Cell Lung Cancer
University Medical Center Groningen 18
Not applicableStudy completedNCT03017885
What this trial is testing

Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy

Who this might be right for
Non-small Cell Lung Cancer
Boehringer Ingelheim 28
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Not applicableLooking for participantsNCT06809764
What this trial is testing

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Who this might be right for
Non-small Cell Lung Cancer
Daiichi Sankyo 150
Testing effectiveness (Phase 2)Looking for participantsNCT07202364
What this trial is testing

YL202 in Patients With Advanced Solid Tumors

Who this might be right for
Non Small Cell Lung CancerColorectal CancerCervical Cancer+1 more
MediLink Therapeutics (Suzhou) Co., Ltd. 100
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Not applicableApproved For MarketingNCT01649284
What this trial is testing

Afatinib Expanded Access Program

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Testing effectiveness (Phase 2)UnknownNCT05519293
What this trial is testing

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
RedCloud Bio 76
Testing effectiveness (Phase 2)Ended earlyNCT04032704
What this trial is testing

Ladiratuzumab Vedotin in Advanced Solid Tumors

Who this might be right for
Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
Seagen Inc. 205
Testing effectiveness (Phase 2)Active Not RecruitingNCT05374603
What this trial is testing

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07549061
What this trial is testing

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

Who this might be right for
Lung Neoplasms
Shanghai Chest Hospital 19
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Large-scale testing (Phase 3)UnknownNCT00706862
What this trial is testing

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Agennix 1,100
Next Page